Overview
- Anthony Letai said the National Cancer Institute has run an improved lab study on ivermectin’s ability to kill cancer cells and expects results within months.
- Letai cautioned that any signals seen so far are not strong and said the drug is not going to be a cure-all for cancer.
- Career scientists at the institute criticized the project as a diversion of taxpayer funds from more promising research.
- Reporters tied the study to leadership signaling greater openness to fringe or off-label ideas, including comments by NIH Director Jay Bhattacharya at a MAHA-hosted event.
- There is no clinical evidence that ivermectin treats cancer in humans, the FDA warns high doses can be dangerous, and clinicians have documented patient harm linked to unsupervised use.